The endoplasmic reticulum stress/unfolded protein response in gliomagenesis, tumor progression and as a therapeutic target in glioblastoma

Biochemical Pharmacology

Volumn 118, Issue , 2016, Pages 1-8

  Peñaranda Fajardo, Natalia M ^a   Meijer, Coby ^a   Kruyt, Frank A E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

ER stress; Glioma; Microenvironment; Therapy; UPR

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 6; NATURAL PRODUCT; PROTEASOME INHIBITOR; PROTEIN IRE1; PROTEIN KINASE; PROTEIN KINASE R LIKE ER KINASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ANGIOGENESIS; APOPTOSIS; CANCER GROWTH; CARCINOGENESIS; CELL DEATH; CELL DIFFERENTIATION; CELL INVASION; CYTOTOXICITY; ENDOPLASMIC RETICULUM STRESS; GLIOBLASTOMA; HUMAN; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR MICROENVIRONMENT; UNFOLDED PROTEIN RESPONSE; ANIMAL; BIOLOGICAL MODEL; CANCER GRADING; DRUG EFFECTS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; TRENDS; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOGENESIS; ENDOPLASMIC RETICULUM STRESS; GLIOBLASTOMA; HUMANS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; NEOPLASM GRADING; TUMOR BURDEN; TUMOR MICROENVIRONMENT; UNFOLDED PROTEIN RESPONSE;

EID: 84964258008     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2016.04.008     Document Type: Review

References (69)

1. [1] Chen, J., McKay, R.M., Parada, L.F., Malignant glioma: lessons from genomics, mouse models, and stem cells. Cell 149 (2012), 36–47.
2. [2] Stupp, R., Mason, W.P., Den Bent, Van., Martin, J., Weller, M., Fisher, B., Taphoorn, M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352 (2005), 987–996.
3. [3] Tanaka, S., Louis, D.N., Curry, W.T., Batchelor, T.T., Dietrich, J., Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?. Nat. Rev. Clin. Oncol. 10 (2013), 14–26.
4. [4] Diehl, J.A., Fuchs, S.Y., Koumenis, C., The cell biology of the unfolded protein response. Gastroenterology 141 (2011), 38–41.
5. [5] Sano, R., Reed, J.C., ER stress-induced cell death mechanisms. Biochim. Biophys. Acta 1833 (2013), 3460–3470.
6. [6] Tsai, Y.C., Weissman, A.M., The unfolded protein response, degradation from the endoplasmic reticulum, and cancer. Genes Cancer 1 (2010), 764–778.
7. [7] Kim, H., Bhattacharya, A., Qi, L., Endoplasmic reticulum quality control in cancer: friend or foe. Anonymous Seminars in Cancer Biology, 2015, Elsevier, 25–33.
8. [8] Wang, M., Kaufman, R.J., The impact of the endoplasmic reticulum protein-folding environment on cancer development. Nat. Rev. Cancer 14 (2014), 581–597.
9. [9] Giampietri, C., Petrungaro, S., Conti, S., Facchiano, A., Filippini, A., Ziparo, E., Cancer microenvironment and endoplasmic reticulum stress response. Mediators Inflamm., 2015, 2015 417281.
10. [10] Schönthal, A.H., Pharmacological targeting of endoplasmic reticulum stress signaling in cancer. Biochem. Pharmacol. 85 (2013), 653–666.
11. [11] Chevet, E., Hetz, C., Samali, A., Endoplasmic reticulum stress-activated cell reprogramming in oncogenesis. Cancer Discov. 5 (2015), 586–597.
12. [12] Bravo, R., Parra, V., Gatica, D., Rodriguez, A.E., Torrealba, N., Paredes, F., et al. Endoplasmic reticulum and the unfolded protein response: dynamics and metabolic integration. Int. Rev. Cell. Mol. Biol. 301 (2013), 215–290.
13. [13] Healy, S.J., Gorman, A.M., Mousavi-Shafaei, P., Gupta, S., Samali, A., Targeting the endoplasmic reticulum-stress response as an anticancer strategy. Eur. J. Pharmacol. 625 (2009), 234–246.
14. [14] Malhotra, J.D., Kaufman, R.J., The endoplasmic reticulum and the unfolded protein response. Anonymous Seminars in Cell & Developmental Biology, 2007, Elsevier, 716–731.
15. [15] Wu, J., Kaufman, R., From acute ER stress to physiological roles of the unfolded protein response. Cell Death Differ. 13 (2006), 374–384.
16. [16] Iurlaro, R., Muñoz-Pinedo, C., Cell death induced by endoplasmic reticulum stress. FEBS J., 2015, 10.1111/febs.13598.
17. [17] Hetz, C., Chevet, E., Harding, H.P., Targeting the unfolded protein response in disease. Nat. Rev. Drug Discov. 12 (2013), 703–719.
18. [18] Cullinan, S.B., Diehl, J.A., PERK-dependent activation of Nrf2 contributes to redox homeostasis and cell survival following endoplasmic reticulum stress. J. Biol. Chem. 279 (2004), 20108–20117.
19. [19] Hollien, J., Lin, J.H., Li, H., Stevens, N., Walter, P., Weissman, J.S., Regulated Ire1-dependent decay of messenger RNAs in mammalian cells. J. Cell Biol. 186 (2009), 323–331.
20. [20] Hetz, C., The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nat. Rev. Mol. Cell Biol. 13 (2012), 89–102.
21. [21] Shoulders, M.D., Ryno, L.M., Genereux, J.C., Moresco, J.J., Tu, P.G., Wu, C., et al. Stress-independent activation of XBP1s and/or ATF6 reveals three functionally diverse ER proteostasis environments. Cell Rep. 3 (2013), 1279–1292.
22. [22] Suh, D.H., Kim, M., Kim, H.S., Chung, H.H., Song, Y.S., Unfolded protein response to autophagy as a promising druggable target for anticancer therapy. Ann. N.Y. Acad. Sci. 1271 (2012), 20–32.
23. [23] Deegan, S., Saveljeva, S., Gorman, A.M., Samali, A., Stress-induced self-cannibalism: on the regulation of autophagy by endoplasmic reticulum stress. Cell. Mol. Life Sci. 70 (2013), 2425–2441.
24. [24] Greenman, C., Stephens, P., Smith, R., Dalgliesh, G.L., Hunter, C., Bignell, G., et al. Patterns of somatic mutation in human cancer genomes. Nature 446 (2007), 153–158.
25. [25] Parsons, D.W., Jones, S., Zhang, X., Lin, J.C., Leary, R.J., Angenendt, P., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321 (2008), 1807–1812.
26. [26] Lu, Z., Zhou, L., Killela, P., Rasheed, A.B., Di, C., Poe, W.E., et al. Glioblastoma proto-oncogene SEC61gamma is required for tumor cell survival and response to endoplasmic reticulum stress. Cancer Res. 69 (2009), 9105–9111.
27. [27] Singh, S.K., Hawkins, C., Clarke, I.D., Squire, J.A., Bayani, J., Hide, T., et al. Identification of human brain tumour initiating cells. Nature 432 (2004), 396–401.
28. [28] Gargiulo, G., Cesaroni, M., Serresi, M., de Vries, N., Hulsman, D., Bruggeman, S.W., et al. In vivo RNAi screen for BMI1 targets identifies TGF-β/BMP-ER stress pathways as key regulators of neural-and malignant glioma-stem cell homeostasis. Cancer Cell 23 (2013), 660–676.
29. [29] Jiang, H.Y., Wek, S.A., McGrath, B.C., Lu, D., Hai, T., Harding, H.P., et al. Activating transcription factor 3 is integral to the eukaryotic initiation factor 2 kinase stress response. Mol. Cell. Biol. 24 (2004), 1365–1377.
30. [30] Drogat, B., Auguste, P., Nguyen, D.T., Bouchecareilh, M., Pineau, R., Nalbantoglu, J., et al. IRE1 signaling is essential for ischemia-induced vascular endothelial growth factor-A expression and contributes to angiogenesis and tumor growth in vivo. Cancer Res. 67 (2007), 6700–6707.
31. [31] Chen, X., Iliopoulos, D., Zhang, Q., Tang, Q., Greenblatt, M.B., Hatziapostolou, M., et al. XBP1 promotes triple-negative breast cancer by controlling the HIF1 [agr] pathway. Nature 508 (2014), 103–107.
32. [32] Wang, Y., Alam, G.N., Ning, Y., Visioli, F., Dong, Z., Nor, J.E., et al. The unfolded protein response induces the angiogenic switch in human tumor cells through the PERK/ATF4 pathway. Cancer Res. 72 (2012), 5396–5406.
33. [33] Auf, G., Jabouille, A., Guerit, S., Pineau, R., Delugin, M., Bouchecareilh, M., et al. Inositol-requiring enzyme 1alpha is a key regulator of angiogenesis and invasion in malignant glioma. Proc. Natl. Acad. Sci. U.S.A. 107 (2010), 15553–15558.
34. [34] Dejeans, N., Pluquet, O., Lhomond, S., Grise, F., Bouchecareilh, M., Juin, A., et al. Autocrine control of glioma cells adhesion and migration through IRE1alpha-mediated cleavage of SPARC mRNA. J. Cell Sci. 125 (2012), 4278–4287.
35. [35] Pluquet, O., Dejeans, N., Bouchecareilh, M., Lhomond, S., Pineau, R., Higa, A., et al. Posttranscriptional regulation of PER1 underlies the oncogenic function of IREalpha. Cancer Res. 73 (2013), 4732–4743.
36. [36] Jabouille, A., Delugin, M., Pineau, R., Dubrac, A., Soulet, F., Lhomond, S., et al. Glioblastoma invasion and cooption depend on IRE1alpha endoribonuclease activity. Oncotarget 6 (2015), 24922–24934.
37. [37] Verhaak, R.G., Hoadley, K.A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M.D., et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17 (2010), 98–110.
38. [38] Joseph, J., Conroy, S., Tomar, T., Eggens-Meijer, E., Bhat, K., Copray, S., et al. TGF-β is an inducer of ZEB1-dependent mesenchymal transdifferentiation in glioblastoma that is associated with tumor invasion. Cell Death Dis, 5, 2014, e1443.
39. [39] Fathallah-Shaykh, H.M., Genomic discovery reveals a molecular system for resistance to oxidative and endoplasmic reticulum stress in cultured glioma. Arch. Neurol. 62 (2005), 233–236.
40. [40] Pyrko, P., Schonthal, A.H., Hofman, F.M., Chen, T.C., Lee, A.S., The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas. Cancer Res. 67 (2007), 9809–9816.
41. [41] Suyama, K., Watanabe, M., Sakabe, K., Otomo, A., Okada, Y., Terayama, H., et al. GRP78 suppresses lipid peroxidation and promotes cellular antioxidant levels in glial cells following hydrogen peroxide exposure. PLoS One, 9, 2014, e86951.
42. [42] Suyama, K., Watanabe, M., Sakabe, K., Okada, Y., Matsuyama, D., Kuroiwa, M., et al. Overexpression of GRP78 protects glial cells from endoplasmic reticulum stress. Neurosci. Lett. 504 (2011), 271–276.
43. [43] Epple, L.M., Dodd, R.D., Merz, A.L., Dechkovskaia, A.M., Herring, M., Winston, B.A., et al. Induction of the unfolded protein response drives enhanced metabolism and chemoresistance in glioma cells. PLoS One, 8, 2013, e73267.
44. [44] Hou, X., Liu, Y., Liu, H., Chen, X., Liu, M., Che, H., et al. PERK silence inhibits glioma cell growth under low glucose stress by blockage of p-AKT and subsequent HK2’s mitochondria translocation. Sci. Rep., 5, 2015.
45. [45] Chen, T.C., Wang, W., Golden, E.B., Thomas, S., Sivakumar, W., Hofman, F.M., et al. Green tea epigallocatechin gallate enhances therapeutic efficacy of temozolomide in orthotopic mouse glioblastoma models. Cancer Lett. 302 (2011), 100–108.
46. [46] Sun, S., Lee, D., Ho, A.S., Pu, J.K., Zhang, X.Q., Lee, N.P., et al. Inhibition of prolyl 4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide resistance in malignant glioma via the endoplasmic reticulum stress response (ERSR) pathways. Neuro Oncol. 15 (2013), 562–577.
47. [47] Suzuki, K., Gerelchuluun, A., Hong, Z., Sun, L., Zenkoh, J., Moritake, T., et al. Celecoxib enhances radiosensitivity of hypoxic glioblastoma cells through endoplasmic reticulum stress. Neuro Oncol. 15 (2013), 1186–1199.
48. [48] Contessa, J.N., Bhojani, M.S., Freeze, H.H., Ross, B.D., Rehemtulla, A., Lawrence, T.S., Molecular imaging of N-linked glycosylation suggests glycan biosynthesis is a novel target for cancer therapy. Clin. Cancer Res. 16 (2010), 3205–3214.
49. [49] Contessa, J.N., Bhojani, M.S., Freeze, H.H., Rehemtulla, A., Lawrence, T.S., Inhibition of N-linked glycosylation disrupts receptor tyrosine kinase signaling in tumor cells. Cancer Res. 68 (2008), 3803–3809.
50. [50] Kim, I.Y., Kang, Y.J., Yoon, M.J., Kim, E.H., Kim, S.U., Kwon, T.K., et al. Amiodarone sensitizes human glioma cells but not astrocytes to TRAIL-induced apoptosis via CHOP-mediated DR5 upregulation. Neuro Oncol. 13 (2011), 267–279.
51. [51] Tian, X., Ye, J., Alonso-Basanta, M., Hahn, S.M., Koumenis, C., Dorsey, J.F., Modulation of CCAAT/enhancer binding protein homologous protein (CHOP)-dependent DR5 expression by nelfinavir sensitizes glioblastoma multiforme cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J. Biol. Chem. 286 (2011), 29408–29416.
52. [52] Yoon, M.J., Kang, Y.J., Kim, I.Y., Kim, E.H., Lee, J.A., Lim, J.H., et al. Monensin, a polyether ionophore antibiotic, overcomes TRAIL resistance in glioma cells via endoplasmic reticulum stress, DR5 upregulation and c-FLIP downregulation. Carcinogenesis 34 (2013), 1918–1928.
53. [53] Pyrko, P., Kardosh, A., Wang, W., Xiong, W., Schonthal, A.H., Chen, T.C., HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress. Cancer Res. 67 (2007), 10920–10928.
54. [54] van Roosmalen, I.A., Reis, C.R., Setroikromo, R., Yuvaraj, S., Joseph, J.V., Tepper, P.G., et al. The ER stress inducer DMC enhances TRAIL-induced apoptosis in glioblastoma. SpringerPlus, 3, 2014, 495.
55. [55] Gupta, P., Walter, M.R., Su, Z.Z., Lebedeva, I.V., Emdad, L., Randolph, A., et al. BiP/GRP78 is an intracellular target for MDA-7/IL-24 induction of cancer-specific apoptosis. Cancer Res. 66 (2006), 8182–8191.
56. [56] Park, M.A., Yacoub, A., Sarkar, D., Emdad, L., Rahmani, M., Spiegel, S., et al. PERK-dependent regulation of MDA-7/IL-24-induced autophagy in primary human glioma cells. Autophagy 4 (2008), 513–515.
57. [57] Hamed, H.A., Yacoub, A., Park, M.A., Eulitt, P.J., Dash, R., Sarkar, D., et al. Inhibition of multiple protective signaling pathways and Ad.5/3 delivery enhances mda-7/IL-24 therapy of malignant glioma. Mol. Ther. 18 (2010), 1130–1142.
58. [58] Salazar, M., Carracedo, A., Salanueva, I.J., Hernandez-Tiedra, S., Lorente, M., Egia, A., et al. Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. J. Clin. Invest. 119 (2009), 1359–1372.
59. [59] Kim, T.H., Song, J., Kim, S.H., Parikh, A.K., Mo, X., Palanichamy, K., et al. Piperlongumine treatment inactivates peroxiredoxin 4, exacerbates endoplasmic reticulum stress, and preferentially kills high-grade glioma cells. Neuro Oncol. 16 (2014), 1354–1364.
60. [60] Cho, H.Y., Wang, W., Jhaveri, N., Torres, S., Tseng, J., Leong, M.N., et al. Perillyl alcohol for the treatment of temozolomide-resistant gliomas. Mol. Cancer Ther. 11 (2012), 2462–2472.
61. [61] Jhaveri, N., Agasse, F., Armstrong, D., Peng, L., Commins, D., Wang, W., et al. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells. Cancer Lett. 371 (2016), 240–250.
62. [62] Kardosh, A., Golden, E.B., Pyrko, P., Uddin, J., Hofman, F.M., Chen, T.C., et al. Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib. Cancer Res. 68 (2008), 843–851.
63. [63] Cattaneo, M., Baronchelli, S., Schiffer, D., Mellai, M., Caldera, V., Saccani, G.J., et al. Down-modulation of SEL1L, an unfolded protein response and endoplasmic reticulum-associated degradation protein, sensitizes glioma stem cells to the cytotoxic effect of valproic acid. J. Biol. Chem. 289 (2014), 2826–2838.
64. [64] Alonso-Basanta, M., Fang, P., Maity, A., Hahn, S.M., Lustig, R.A., Dorsey, J.F., A phase I study of nelfinavir concurrent with temozolomide and radiotherapy in patients with glioblastoma multiforme. J. Neurooncol. 116 (2014), 365–372.
65. [65] Penas-Prado, M., Hess, K.R., Fisch, M.J., Lagrone, L.W., Groves, M.D., Levin, V.A., et al. Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. Neuro Oncol. 17 (2015), 266–273.
66. [66] Friday, B.B., Anderson, S.K., Buckner, J., Yu, C., Giannini, C., Geoffroy, F., et al. Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study. Neuro Oncol. 14 (2012), 215–221.
67. [67] Da Fonseca, C.O., Simao, M., Lins, I.R., Caetano, R.O., Futuro, D., Quirico-Santos, T., Efficacy of monoterpene perillyl alcohol upon survival rate of patients with recurrent glioblastoma. J. Cancer Res. Clin. Oncol. 137 (2011), 287–293.
68. [68] Weller, M., Gorlia, T., Cairncross, J.G., van den Bent, M.J., Mason, W., Belanger, K., et al. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology 77 (2011), 1156–1164.
69. [69] Maurel, M., McGrath, E.P., Mnich, K., Healy, S., Chevet, E., Samali, A., Controlling the unfolded protein response-mediated life and death decisions in cancer. Anonymous Seminars in Cancer Biology, 2015, Elsevier, 57–66.